Related Articles
XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second‑line setting involving the sequential administration of XELOX and XELIRI
Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first‑line treatment for Japanese patients with metastatic colorectal cancer
Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer
Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials
Irinotecan plus raltitrexed as second‑line chemotherapy for metastatic colorectal cancer: A retrospective study